Cost for cancer drugs triples in Canada, still no national drug plan
Data shows cancer medications account for about 15% of all spending on pharmaceuticals.
Pfizer raises concerns on probe of Ottawa’s pandemic response
Raises confidentiality related to requirement to produce documents related to the production and purchase of a vaccine for COVID-19.
UK is buying 90M coronavirus vaccine doses
Has accessed to candidates being developed by a Pfizer, BioNTech, and another experimental vaccine researched by Valneva.
Novartis pays $678M to resolve suit over sham doctor outings
Company splurged on speaking fees, exorbitant meals, and top-shelf alcohol to get doctors to prescribe Novartis’s drugs.
Apotex Pharmachem produces hand sanitizer
The Brantford, Ont.-based division of Apotex is producing 1,200 litres of sanitizer in the coming weeks
Bora Pharmaceuticals acquires GSK Mississauga facility
The transaction is expected to be complete by the end of 2020.
Novartis plans to cut 2,100 jobs in Switzerland, Britain
Swiss pharmaceuticals giant hopes to lower its overall headcount worldwide to below 100,000, from about 126,000 today.
Freeland to return to NAFTA talks in Washington this week
Intense discussions continue but stalling over dispute settlement mechanism.
Valeant invests $10M in Laval plant upgrades
Enhances manufacturing capabilities and export capacity.
Valeant invests $8M in Manitoba manufacturing plant
Company to transfer North American production of Xifaxan and Apriso to Steinbach facility.
Lawyer pushing Cold fX class action is ‘manufacturing’ case: Valeant
Pharmaceutical firm’s lawyer cites an absence of an easily defined class of complainants.
Cold-fX case should receive class action approval: lawsuit
Makers accused of misleading the public about remedy’s short-term effectiveness.
Overnight suspense over TPP, on verge of completion
Trade deal stalled over next-gen pharmaceuticals that delayed resolution of other issues.
Canada Drugs faces US charges for counterfeit drugs
Online pharmacy based in Winnipeg accused of smuggling, money laundering and conspiracy.
CETA to increase drug costs by up to $1.65B
Analysts says delaying the arrival of cheaper generic drugs will add up to 13%.